<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2324">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04366934</url>
  </required_header>
  <id_info>
    <org_study_id>2020-021</org_study_id>
    <nct_id>NCT04366934</nct_id>
  </id_info>
  <brief_title>Study of the Pathogenesis of Olfactory Disorders in COVID-19</brief_title>
  <acronym>COVIDSMELL</acronym>
  <official_title>Study of the Pathogenesis of Olfactory Disorders in COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Pasteur</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hôpital Lariboisière, AP-HP</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut Pasteur</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a case-control study to characterize the molecular and cellular anomalies of
      the olfactory epithelium of COVID-19 patients with isolated anosmia, by comparison with the
      olfactory epithelium of non-infected subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Olfactory and taste dysfunctions are common and early onset in COVID-19, especially in pauci
      symptomatic patients, and may be the main clinical manifestations of the infection. Olfactory
      dysfunction could result from infection of the olfactory system by SARS-CoV-2 or from
      inflammation induced by the virus. While the recent development of COVID-19 pulmonary lesion
      research has revealed a viral, inflammatory and vascular origin, factors that cause olfactory
      disorders in COVID-19 are just beginning.

      Acute anosmia observed in some patients with COVID-19 could result from:

        -  the direct infection of olfactory sensory neurons or neural stem cells of the olfactory
           mucosa,

        -  an underlying inflammation of the olfactory mucosa, leading to possible
           neurodegeneration of olfactory sensory neurons, and neural stem cells of the olfactory
           mucosa, by analogy with the respiratory viruses responsible for chronic rhinosinusitis.

      It is therefore necessary to conduct a virological, cellular, immunological and inflammatory
      study of the olfactory epithelium from COVID-19 patients with isolated anosmia to identify
      the origin of these olfactory disorders.

      This study is a case-control study to characterize the molecular and cellular anomalies of
      the olfactory epithelium of COVID-19 patients with isolated anosmia, by comparison with the
      olfactory epithelium of non-infected subjects.

      Following measures will be performed at inclusion :

        -  Taste and olfactory function evaluation by a self-questionnaire taste and smell survey
           (TTS) and a visual analogue scale (VAS)

        -  Nasal swab sampling for collection of epithelium cells and olfactory mucus.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 4, 2020</start_date>
  <completion_date type="Anticipated">September 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 15, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Molecular and cellular defects in olfactory epithelium</measure>
    <time_frame>30 months</time_frame>
    <description>Ratio of olfactory sensory cells in the nasal cytological sample</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biological mechanisms involved in the pathogenesis of the disease</measure>
    <time_frame>30 months</time_frame>
    <description>Multiple measurements will be analyzed to characterize the immune and inflamatory status of the olfactory mucosa (presence of infiltrated immune cells, activation state of the immune cells in the epithelium, cytokine and interleukin level)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Epidemiological characteristics</measure>
    <time_frame>30 months</time_frame>
    <description>Demographic variables (sex, age, blood type), risk factors (tobacco, overweight, diabetes, rhinosinusitis disease, respiratory allergy)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Olfactory and taste dysfunction</measure>
    <time_frame>30 months</time_frame>
    <description>Self-questionnaire taste and smell survey (TTS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Olfactory and taste dysfunction</measure>
    <time_frame>30 months</time_frame>
    <description>Visual analogue scale (VAS) (units from 0 normal perception to 100 no perception)</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Coronavirus Infection</condition>
  <condition>Severe Acute Respiratory Syndrome</condition>
  <condition>Sars-CoV2</condition>
  <arm_group>
    <arm_group_label>COVID-19 patients</arm_group_label>
    <description>Subject consulting in the Lariboisière hospital (Paris) in the context of the COVID-19 screening care for a suspected SARS-CoV-2 infection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control subjects</arm_group_label>
    <description>Subject consulting in the ear, nose and throat department at the Lariboisière hospital (Paris) with no biologically confirmed COVID-19 or suspected COVID-19 in the past 8 weeks, and no symptoms suggestive of COVID-19 or another respiratory disease and therefore no recent anosmia or ageusia</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Nasal swab</intervention_name>
    <description>Nasal swab</description>
    <arm_group_label>COVID-19 patients</arm_group_label>
    <arm_group_label>Control subjects</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Taste and olfactory function evaluation</intervention_name>
    <description>Taste and olfactory function evaluation</description>
    <arm_group_label>COVID-19 patients</arm_group_label>
    <arm_group_label>Control subjects</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Nasal swabs
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        COVID-19 patients and control subjects
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        COVID-19 patients

          -  Age &gt; 18 years

          -  Subject consulting in the context of the COVID-19 screening care for a suspected
             SARS-CoV-2 infection

        Controls

          -  Age &gt; 18 years

          -  Subject consulting in the ear, nose and throat department with no biologically
             confirmed COVID-19 or suspected COVID-19 in the past 8 weeks, and no symptoms
             suggestive of COVID-19 or another respiratory disease and therefore no recent anosmia
             or ageusia

        Exclusion Criteria (both COVID-19 patients and controls):

          -  Refusal or contraindication to nasal swab

          -  Presence of nasal sinus pathology
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Françoise LAZARINI, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Institut Pasteur</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Françoise LAZARINI, PhD</last_name>
    <phone>+33 (0) 1 44 38 92 74</phone>
    <email>francoise.lazarini-serandour@pasteur.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hôpital Lariboisière, Policlinique</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caroline APARICIO, MD</last_name>
      <phone>+33(0)149958124</phone>
      <email>caroline.aparicio@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Carolina APARICIO, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Lariboisière, Service ORL</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Charlotte HAUTEFORT, MD</last_name>
      <phone>+33(0)149959197</phone>
      <email>charlotte.hautefort@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Charlotte HAUTEFORT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Benjamin VERILLAUD, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>April 22, 2020</study_first_submitted>
  <study_first_submitted_qc>April 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 29, 2020</study_first_posted>
  <last_update_submitted>May 5, 2020</last_update_submitted>
  <last_update_submitted_qc>May 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SARS-CoV-2</keyword>
  <keyword>Sense of smell disorders</keyword>
  <keyword>Anosmia</keyword>
  <keyword>Olfaction</keyword>
  <keyword>Nasal neuroepithelium</keyword>
  <keyword>Olfactory mucosa</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

